%0 Clinical Trial, Phase II
%T Melanoma neoantigen vaccines: Are we getting more personal now?
%A Latifyan S
%A Haanen JB
%J Med
%V 5
%N 4
%D 2024 Apr 12
%M 38614074
暂无%R 10.1016/j.medj.2024.03.004
%X KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.